AstraZeneca fights HMRC over transfer pricing
A tax dispute between global pharmaceutical firm, AstraZeneca, and HM Revenues and Customs (HMRC) has been deferred until April 2010, with the outcome of the case expected to have an impact on multinationals and their transfer pricing regimes.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: